secwatch.observer — SEC 8-K summary
======================================

Issuer:     Edwards Lifesciences Corp (EW)
CIK:        0001099800
Form:       8-K
Filed at:   2022-01-26T23:59:59+00:00
Accession:  0001099800-22-000002
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Edwards Q4 sales $1.33B (+12% YoY); adjusted EPS $0.51; guides FY22 sales $5.5-6.0B
--------------------------------------------------------------------------------

- Q4 sales $1.33B, up 12% (13% underlying); TAVR sales $872M (+12%); TMTT $25M.
- Q4 GAAP EPS $0.53; adjusted EPS $0.51.
- Full year 2021 sales $5.2B (+19%); adjusted EPS $2.22 (+19% YoY).
- FY22 guidance: sales $5.5-6.0B (low double-digit growth); adjusted EPS $2.50-$2.65; Q1 sales $1.27-1.35B.
- Completed enrollment of CLASP IID and EARLY TAVR trials; FDA approved SAPIEN 3 with Alterra.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1099800/000109980022000002/0001099800-22-000002-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1099800/000109980022000002/ew-20220126.htm
  HTML page:      https://secwatch.observer/filing/0001099800-22-000002

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer